Buy Alert: 10 Stocks Analysts Upgraded on Wednesday

Page 3 of 3

4. Mercury Systems (NASDAQ:MRCY)

Market Cap: $5.38 billion

Average Upside Potential: 24%

Number of Hedge Fund Holders: 33

JPMorgan analyst Seth Seifman upgraded Mercury Systems from Neutral to Overweight on November 11 and set a $102 price target after the company’s fiscal first-quarter report. The rating moved up even as the target came down from its earlier level.

Mercury builds processing, power and secure electronics for defense programs, including missile defense and space. Revenue grew 12.4% to a first-quarter record, bookings grew even faster, net debt fell from a year earlier, and backlog reached a record near $2.1 billion. CFO Dave Farnsworth also added the chief operating officer title. Adjusted EBITDA grew 58.6%, and management raised its outlook for fiscal 2027.

Investors had long wanted proof that the company’s turnaround was converting into demand, and the latest quarter gave them more of it. Mercury is also working with a software partner on AI tools for material planning and factory operations, aimed at converting backlog faster. The shares rose the day after the report, and hedge fund ownership of the stock has edged up recently. Mercury Systems (MRCY) Is Sitting On A Record Pile Of Orders was our take on the backlog build, which the new quarter extended.

3. Delek US Holdings (NYSE:DK)

Market Cap: $4.07 billion

Average Upside Potential: 26%

Number of Hedge Fund Holders: 41

Freedom Broker analyst Sergey Pigarev upgraded Delek US Holdings from Hold to Buy on November 11 and nudged his price target up to $88. He credited a strong third quarter built on wider crack spreads, full runs at all four refineries and higher margin capture. Crack spreads, the gap between crude costs and the price of refined fuels, widened in the quarter, and he expects earnings to fall as they normalize.

Delek refines crude oil into fuels at four US refineries. Adjusted net income nearly doubled to $843.0 million in the quarter, and the company used the cash to cut net debt. The board raised the quarterly dividend by about 18% and stepped up buybacks, with $100 million planned for the fourth quarter.

Delek also expects roughly $425 million of small-refinery-exemption proceeds in the fourth quarter and plans to repay its term loan. Raymond James trimmed its target the same week while keeping an Outperform rating on the stock. Refiners sit alongside other energy names in 10 Energy and Power Stocks Drawing Strong Reactions From Jim Cramer, a list we published recently.

2. Alpha Tau Medical (NASDAQ:DRTS)

Market Cap: $1.30 billion

Average Upside Potential: 46%

Number of Hedge Fund Holders: 15

Piper Sandler analyst Allison Bratzel upgraded Alpha Tau Medical from Neutral to Overweight on November 11 and raised her price target to $22 from $8, reversing a Neutral call she made earlier this year. She described Alpha DaRT as a differentiated local alpha-radiation platform with potential across several solid tumors, and she expects a catalyst-rich year ahead.

Alpha Tau is an Israeli clinical-stage company whose Alpha DaRT places tiny alpha-emitting seeds directly inside tumors. Its ReSTART trial, a US pivotal study in recurrent cutaneous squamous cell carcinoma, has finished enrolling its patients. The company has begun a modular application to the FDA, where the therapy holds Breakthrough Device Designation.

The upgrade comes after a large move for a clinical-stage developer, with shares up about 177% this year. The company held about $100.64 million in cash at last report. Barclays also rates the stock Overweight, and the clinical program extends to cancers of internal organs. Alpha Tau is expected to report third-quarter results around November 19. Cancer-focused names like this one are covered in 11 Best Cancer Stocks to Invest In Now.

1. Capricor Therapeutics (NASDAQ:CAPR)

Market Cap: $652.32 million

Average Upside Potential: 137%

Number of Hedge Fund Holders: 32

Jones Trading analyst Catherine Novack upgraded Capricor Therapeutics from Hold to Buy on November 11 with a $25 price target, calling the risk and reward asymmetric ahead of the FDA decision on deramiocel, due later this month. She puts the odds of a complete response letter at 65%, with downside near 70%, and sees about 2.5 times upside if the drug is approved.

Capricor develops deramiocel, a cell therapy for Duchenne muscular dystrophy. An FDA advisory committee opposed the cardiomyopathy indication earlier this year, so the company refocused its application on upper-limb skeletal muscle function after HOPE-3 data. The FDA inspection ended with a Form 483 listing a single observation, and Capricor plans to launch on its own, without NS Pharma, with arbitration over that dispute expected next year.

Capricor reported third-quarter results the day before the upgrade, and a group of clinicians treating Duchenne patients has written to the FDA in support of the therapy. Shares jumped about a quarter on the call. Could New Long-Term Data Support Capricor’s Duchenne Therapy? was our earlier look at the data behind the case.

READ NEXT: A Rejected Vote Pushes Capricor (CAPR) Toward A Narrower Path and Nvidia (NVDA) or Apple (AAPL): Which Is the Better Bet on Dan Ives’ $4 Trillion AI Wave?

Follow Insider Monkey on Google News.

Page 3 of 3